The Conversation (0)
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017
Feb. 26, 2018 04:28PM PST
Pharmaceutical InvestingAkcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today reported financial results for the fourth quarter and year ended December 31, 2017. Akcea is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases. As quoted in the press release: “With our marketing submissions accepted in the US, EU and Canada, …
Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today reported financial results for the fourth quarter and year ended December 31, 2017. Akcea is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases.
As quoted in the press release:
“With our marketing submissions accepted in the US, EU and Canada, we continue to focus our efforts on the regulatory process and on preparation for the mid-2018 launch of volanesorsen quickly after our potential approvals,” said Paula Soteropoulos, president and chief executive officer of Akcea. “In addition, we completed enrollment on our Phase 2b study of AKCEA-APO(a)-LRx and initiated three Phase 2 studies with AKCEA-APOCIII-LRx and AKCEA-ANGPTL3-LRx expanding the number of indications across both broad and rare diseases that we are pursuing with our novel pipeline of therapeutics.”
